Investors sentiment decreased to 1.03 in Q4 2016. Endurant Capital Management LP owned 0.07% of Clovis Oncology worth $2,028,000 at the end of the most recent quarter. It turned negative, as 30 investors sold Clovis Oncology Inc shares while 48 reduced holdings. 38 funds opened positions while 42 raised stakes. Hsbc Public Ltd Company owns 5,475 shares or 0% of their United States portfolio. Sanctuary Wealth Advisors Llc, a California-based fund reported 84,076 shares. Pictet Asset Management Limited holds 195,285 shares or 0.03% of its portfolio.
Clovis Oncology, Inc. (NASDAQ:CLVS) has been the object of insider selling activity recently. Tiaa Cref Inv Lc reported 273,070 shares or 0.01% of all its holdings. PNC Financial Services Group Inc. now owns 2,800 shares of the biopharmaceutical company’s stock worth $179,000 after buying an additional 100 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. now owns 2,400 shares of the biopharmaceutical company’s stock valued at $107,000 after buying an additional 400 shares in the last quarter. Redmile Gru Inc Limited Com accumulated 1.62M shares or 6.2% of the stock. Wellington Management Group LLP boosted its stake in shares of Clovis Oncology by 10,143.6% in the first quarter. Renaissance Techs Ltd Liability Company holds 0.01% or 82,100 shares in its portfolio. 183,693 are owned by Voloridge Inv Mgmt Limited Liability Company.
06/19/2017 – Clovis Oncology, Inc. was upgraded to “neutral” by analysts at Chardan Capital. Stifel has 13,017 shares for 0% of their portfolio.
Since March 15, 2017, it had 0 buys, and 3 insider sales for $528,600 activity. “With best-case data in hand, we think Clovis should be a prime takeout candidate, and we reiterate our OP rating on the stock“. The stock’s average target of $42.67 is -52.67% below today’s ($90.15) share price. The stock of Clovis Oncology Inc (NASDAQ:CLVS) has “Overweight” rating given on Wednesday, May 17 by JP Morgan. Therefore 57% are positive. Based on a recent bid, the stock is trading 12.76% away from it’s 52- week high and 630.34% away from its 52 week low. $33.50’s average target is -40.81% below currents $56.6 stock price. On average, equities research analysts expect that Clovis Oncology will post ($4.95) EPS for the current fiscal year. They now have a Dollars 50 price target on the stock.
06/19/2017 – Clovis Oncology, Inc. had its “buy” rating reiterated by analysts at Bank of America Merrill Lynch. The firm has “Outperform” rating by RBC Capital Markets given on Friday, May 5. Mizuho maintained it with “Neutral” rating and $23.0 target in Wednesday, August 24 report.
In other Clovis Oncology news, insider Gillian C. Ivers-Read sold 3,000 shares of the stock in a transaction dated Thursday, June 15th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company.
03/14/2017 – Clovis Oncology, Inc. had its ” rating reiterated by analysts at Piper Jaffray. The stock has “Buy” rating by J.P. Morgan on Thursday, June 1. Clovis Oncology Inc (NASDAQ:CLVS) has risen 282.71% since June 19, 2016 and is uptrending. Credit Suisse Group reissued an “outperform” rating and issued a $74.00 price target on shares of Clovis Oncology in a report on Tuesday, April 18th. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.43) by $0.10.
Clovis Oncology, Inc., launched on April 20, 2009, is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other global markets.